摘要
目的观察醒脑静治疗急性脑梗死后全身炎症反应综合征(SIRS)的临床疗效。方法将60例患者随机均分为脑复康治疗组(30例)与醒脑静治疗组(30例),观察两组患者治疗前后美国国立卫生研究院卒中量表(NIHSS)评分及C反应蛋白(CRP)水平情况。结果治疗后患者NIHSS评分,醒脑静治疗组明显低于脑复康治疗组(P<0.05);醒脑静治疗组患者CRP水平明显低于脑复康治疗组(P<0.05);醒脑静治疗组多器官功能障碍综合征(MODS)发生率为16.66%,脑复康治疗组MODS发生率为40.00%。结论醒脑静治疗急性脑梗死致全身炎症反应综合征的临床疗效显著,能明显干预急性脑梗死致全身炎症反应及多器官功能障碍综合征的发生。
Objective To investigate the clinical efficacy of Xingnaojing Iinjection in the treatment of systemic inflammatory response syndrome （SIRS） caused by acute cerebral infarction. Methods Sixty cases of SIRS were randomized into two groups,the Xingnaojing Iinjection group （30 cases） and the piracetam group（30 cases）. The changes of NIHSS score and high-sensitivity C-reaction protein（hs-CRP） level be- fore and after treatment were observed and compared between the two groups. Results The NIHSS score after treatment in the Xingnaojing group was lower than that in the piracetam group obviously（ P 〈 0.05）; the hs- CRP level in the Xingnaojing group also was lower than that in the piracetam group obviously（P〈0. 05）.The incidence of multiple organ dysfunction syndrome（MODS） was 16.66% in the Xingnaojing injection group and 40.00% in the piraeetam group. Conclusion Xingnaojing Injection has significantly clinical efficacy in the treatment of SIRS and can significantly interfere the occurrence of SIRS and MODS caused by acute cerebral infarction.
出处
《中国药业》
CAS
2011年第24期76-77,共2页
China Pharmaceuticals
关键词
急性脑梗死
全身炎症反应综合征
醒脑静
C反应蛋白
acute cerebral infarction
systemic inflammatory reaction syndrome
Xingnaojing injection
C - reactive protein
